Develops patented first-in-class therapeutics—selective Nox4 inhibitors and Nrf2 activators—that protect against and can reverse age-associated established fibrosis. Initial targets are idiopathic pulmonary fibrosis and fibrosis in Duchenne muscular dystrophy.